CD8A and myeloid sarcoma: Aligned with this hypothesis, a positive correlation was reported by Von Essen et al. between the percentage of CSF CD8+ CD20+ cells at baseline and the number of new T2 lesions after 48 weeks of DMF treatment in PP-MS [32].